Aspirin may improve 3-month survival for patients critically ill with COVID-19

Antiplatelet drugs such as aspirin have little effect on the need for life support in COVID-19, but they may improve survival in the following months according to a new international study led in the UK by researchers at the University of Bristol and Imperial College London.
Source: University of Bristol news - Category: Universities & Medical Training Tags: Health, Research; Faculty of Health Sciences, Translational Health Sciences, Faculty of Health Sciences, Population Health Sciences, Faculty of Health Sciences, Bristol Medical School; Press Release Source Type: news